ABL extends antibody agreement in $220m deal with WuXi Biologics
ABL will use WuXi’s platforms in an extended agreement for the development and commercialization of its bispecific antibodies, using the recently launched WuXiBody platform.
Archives for February 27, 2019
Allogene builds allogeneic CAR-T site, looking ahead to ‘commercial product’
Allogene enters a lease agreement to develop a 118,000-square-foot site for the manufacture of allogeneic CAR-T therapies.
AbbVie and Voyager develop gene therapies for Parkinson's
AbbVie expands partnership with Voyager for the R&D of vectorized antibodies for the treatment of Parkinson’s disease gene therapies.